There are currently 967 clinical trials in Salt Lake City, Utah looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Utah, Huntsman Cancer Institute/University of Utah, Huntsman Cancer Institute and LDS Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Long-term COVID and Rehabilitation
NCT05373043
Recruiting
The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress and inflammation associated with aging and further induced by COVID-19. The investigators expected outcomes will have an important positive impact because they will provide scientifically sound recommendations for rehabilitation to improve vascular endothelial function... Read More
Gender:
All
Ages:
All
Trial Updated:
10/30/2023
Locations: VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah
Conditions: Long-COVID
Register for Updates
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
NCT04782258
Recruiting
The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)
Gender:
All
Ages:
Between 28 days and 18 years
Trial Updated:
10/30/2023
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Register for Updates
Progression of Early Atrophic Lesions
NCT05959005
Recruiting
Early atrophic age-related macular degeneration (AMD) represents an important time window in the course of so far untreatable atrophic AMD, as patients typically experience only some degree of visual dysfunction, while being at significant risk for marked further loss of vision. To allow the precise evaluation of upcoming therapeutic interventions, a better understanding of the manifestation and variable disease progression is needed. This project aims to investigate refined tools to detect and... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
10/28/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Age-Related Macular Degeneration
Register for Updates
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
NCT05082519
Recruiting
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight. This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy... Read More
Gender:
All
Ages:
Between 10 years and 25 years
Trial Updated:
10/25/2023
Locations: Primary Children's Hospital, Salt Lake City, Utah
Conditions: B-cell Acute Lymphoblastic Leukemia, Obesity
Register for Updates
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646
Recruiting
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an... Read More
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
10/24/2023
Locations: ACTION3 Investigational Site 7, Salt Lake City, Utah
Conditions: FSGS
Register for Updates
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
NCT02000115
Recruiting
The objective of the PORTICO pivotal IDE trial is to evaluate the safety and effectiveness of the St Jude Medical (SJM) Portico Transcatheter Heart Valve and Delivery Systems (Portico) in the treatment of severe symptomatic aortic stenosis via transfemoral and alternative delivery methods in high risk and extreme risk patients.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/24/2023
Locations: University of Utah Hospital, Salt Lake City, Utah
Conditions: Aortic Valve Stenosis
Register for Updates
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
NCT05172024
Recruiting
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatien... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: Bateman Horne Center, Salt Lake City, Utah +4 locations
Conditions: SARS-CoV2 Infection
Register for Updates
Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment
NCT06087991
Recruiting
This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah. Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED bupreno... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Opioid Abuse
Register for Updates
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT04910685
Recruiting
This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. Parts 1 and 2 will enroll patients with ISM. Patients enrolled in Part 1 or Part 2 will roll over onto Part 3 to receive treatment with BLU-263 in an open-label fashion following completion of the earlier Part. Part M will enrol... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
10/20/2023
Locations: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
Conditions: Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome
Register for Updates
Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence
NCT05634005
Recruiting
Determine whether clinical decision support (best practice advisory) improves provider adherence to transfusion guidelines for all four major blood components (red blood cells, plasma, platelets, and cryoprecipitate) using a randomized study design to reduce risk of bias. Alerts will be visible to the experimental ordering provider group, while they will not be visible to the control. Both groups still have access to information about best practices: local clinical transfusion guidelines are ava... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/20/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Anemia, Thrombocytopenia, Coagulopathy, Mild, Hypofibrinogenemia
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: Olympus Family Medicine, Salt Lake City, Utah +1 locations
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
NCT03152058
Recruiting
This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant (LAC) to determine if this regimen will improve pregnancy outcomes. All enrolled patients will receive certolizumab, and pregnancy outcomes will be compared to those of women with APS and repeatedly positive tests for LAC enrolled... Read More
Gender:
Female
Ages:
Between 18 years and 40 years
Trial Updated:
10/17/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder
Register for Updates